TrueScale Capitals leads Series B2 funding for Advamedica
Boston, 27th July 2021: Advamedica has raised $6 million in a Series B2 funding round led by TrueScale
Read more
In the quest of unraveling and
demystifying the micro world of
biomaterials
demystifying the micro world of
biomaterials
In the quest of unraveling and demystifying the micro world of biomaterials
Innovative Platform
Biomaterials Expertise
Surgeries, Trauma, Woundcare
We combine our long biomaterials expertise with the power of proprietary manufacturing platform to develop novel hemostatic, surgical and wound care products. Current area of focus is in improving patient outcomes in pre-hospital, intra-operative, and post-operative clinical settings.
About Us
Hemostasis. Surgical Care. Advanced Woundcare.
Solving age-old problems using novel biomaterials
Play Video
Strong Bioadhesion
Hemostat Patch with Sealant Features
Ease of Removal
*Axiostat uses Protonated Bioadhesive Technology developed by Advamedica which is approved in 40+ countries. Axiostat Patch: FDA 510k K202830, Axiostat Chitosan Haemostatic Dressing: FDA 510k K172324. For more info, visit axiostatusa.com
News Updates
Advamedica Receives FDA Clearance for Axiostat Hemostatic Patch
A biomaterial-focused MedTech startup has announced FDA 510(k) clearance of its hemostatic product...
Read more
Advamedica selected to pitch for Medtech Innovator US Military Pitch
Advamedica has been selected for MedTech Innovator US Military Pitch (May 2020) to pitch its Military...
Read more
Omidyar Network leads Series B1 funding for Advamedica
Advamedica has raised $5.2 Mn in Series B1 round of funding led by Omidyar Network, along with participation...
Read more
Advamedica announces world-class scientific advisory board
Advamedica has announced its top-notch scientific advisory board and research collaboration...
Read more
Axiostat receives US FDA clearance
US FDA granted 510(k) clearance to Axiostat Chitosan Hemostatic Dressing, which is cleared...
Read more
Team
Leo Mavely
Founder & President
Advamedica Inc.
Leo Mavely is the Founder & President of Advamedica Inc. He is passionate about medtech innovations for unmet healthcare needs, and has been featured by Fortune Magazine in 40 under 40 business leaders and by Entrepreneur Magazine in 35 under 35 Game-Changing Entrepreneurs. He holds a Bachelor’s degree in Bioengineering.
Oscar Rospigliosi
Senior Commercial Consultant - USA
Advamedica Inc.
Oscar Rospigliosi is a Senior MedTech executive with broad experience in medical device sales and marketing. He was the CEO & Director at Scion Biomedical and prior to that he was a CEO at Bolton Medical Group, guiding the company from $4.5mn in annual revenues to $80mn in cardio-thoracic market. With the introduction of a unique abdominal stent graft product line, Mr. Rospigliosi was able to drive sales to over $50Mn with greater than 10% growth year over year.
Dr. Shiladitya Sengupta
Associate Professor of Medicine
Harvard Medical School
Dr. Sengupta serves as the Associate Professor of Medicine at HMS and as the Associate Professor of Health Sciences and Technology at MIT. Dr. Sengupta received his PhD from University of Cambridge as a British Chevening and Nehru Scholar, and is a recipient of the TR35 Innovator Award from the MIT Technology Review Magazine and the Era of Hope Scholar Award from the US Department of Defense.
Advisor - Advamedica Inc.
Dr. S.V. Mahadevan
Professor of Emergency Medicine
Stanford University Medical Centre
Dr. Mahadevan is a Professor of Emergency Medicine at Stanford University where he has been a recipient of numerous teaching awards. He also serves as the Director of Global Affairs and Strategy for Stanford Medicine. He received his medical degree from David Geffen School of Medicine at UCLA.
Advisor - Advamedica Inc.
Investors
TrueScale Capital is a venture growth specialist firm which partners with tested founders who are demonstrating meaningful revenue and growth in large target markets in a capital-efficient manner.
Omidyar Network invests in entrepreneurs and their visionary ideas to create opportunities for people to improve their own lives, their communities, and the world around them.
UC-RNT Fund an investment fund sponsored by Tata Sons Chairman Emeritus, Ratan Tata (RNT Associates) and University of California.
Accel is a globally reputed venture capital firm that nurtures forward-thinking, category-defining enterprises.
Chiratae Ventures (formerly IDG Ventures India) is a leading India-focused venture capital fund.